drugset / Trial / NCT00096239

CP-547,632 in Treating Patients With Recurrent or Persistent Ovarian Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer

NCT00096239

Open-labelTreatment

Summary

RATIONALE: CP-547,632 may stop the growth of tumor cells by blocking the enzymes necessary for their growth and by stopping blood flow to the tumor. PURPOSE: This phase II trial is studying how well CP-547,632 works in treating patients with recurrent or persistent ovarian cancer, primary peritoneal cancer, or fallopian tube cancer.

Timeline

Start
2004-12
Primary completion
Completion
2005-02

Drugs

EvaluationDrugModalityDoseRoute
Subject OSI-632 Small molecule Oral